Ameriprise
AXSM icon

Ameriprise’s Axsome Therapeutics AXSM Stock Holding History

Ameriprise’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$105M Buy
428,079
+251,765
+143% +$54.6M 0.02% 588
2026
Q1 		$29.8M Buy
176,314
+76,398
+76% +$13.2M 0.01% 1157
2025
Q4 		$18.2M Sell
99,916
-8,320
-8% -$1.16M ﹤0.01% 1479
2025
Q3 		$13.1M Buy
108,236
+38,152
+54% +$4.3M ﹤0.01% 1708
2025
Q2 		$7.32M Buy
70,084
+54,068
+338% +$5.73M ﹤0.01% 2050
2025
Q1 		$1.87M Sell
16,016
-2,222
-12% -$253K ﹤0.01% 2938
2024
Q4 		$1.54M Sell
18,238
-179,697
-91% -$16.5M ﹤0.01% 3060
2024
Q3 		$17.8M Buy
197,935
+152,620
+337% +$13.3M ﹤0.01% 1402
2024
Q2 		$3.65M Buy
45,315
+32,728
+260% +$2.42M ﹤0.01% 2534
2024
Q1 		$1M Buy
12,587
+6,438
+105% +$540K ﹤0.01% 3163
2023
Q4 		$489K Sell
6,149
-22,993
-79% -$1.54M ﹤0.01% 3455
2023
Q3 		$2.04M Sell
29,142
-514
-2% -$38.4K ﹤0.01% 2805
2023
Q2 		$2.13M Buy
29,656
+22,565
+318% +$1.66M ﹤0.01% 2839
2023
Q1 		$437K Buy
7,091
+1,166
+20% +$76.6K ﹤0.01% 3478
2022
Q4 		$457K Buy
5,925
+10
+0.2% +$598 ﹤0.01% 3440
2022
Q3 		$265K Buy
+5,915
New +$296K ﹤0.01% 3618

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Ameriprise's AXSM Position: Q2 2026 in Review

Ameriprise increased its Axsome Therapeutics (AXSM) stake by 143% in Q2 2026, buying an estimated $54.6M and bringing the position to 428,079 shares worth $105M. The position accounts for 0.02% of the portfolio, ranked #588.

Ameriprise first reported a position in AXSM in Q3 2022 and has held it in 16 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Ameriprise held 428,079 shares of Axsome Therapeutics worth $105M as of Q2 2026.
  • Ameriprise bought 251,765 Axsome Therapeutics shares in Q2 2026, an estimated $54.6M.
  • Axsome Therapeutics made up 0.02% of Ameriprise's portfolio in Q2 2026, its #588 holding.
  • Ameriprise first reported a position in Axsome Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.